Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake

BACKGROUND Despite growing preclinical evidence that glucagon-like peptide1 receptor agonists (GLP-1RAs) could be repurposed to treat alcohol use disorder (AUD), clinical evidence is scarce. Additionally, the potential impact of dipeptidyl peptidase-4 inhibitors (DPP-4Is) on alcohol intake is largel...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:The Journal of Clinical Investigation
المؤلفون الرئيسيون: Mehdi Farokhnia, John Tazare, Claire L. Pince, Nicolaus Bruns VI, Joshua C. Gray, Vincent Lo Re III, David A. Fiellin, Henry R. Kranzler, George F. Koob, Amy C. Justice, Leandro F. Vendruscolo, Christopher T. Rentsch, Lorenzo Leggio
التنسيق: مقال
اللغة:الإنجليزية
منشور في: American Society for Clinical Investigation 2025-05-01
الموضوعات:
Endocrinology
Neuroscience
الوصول للمادة أونلاين:https://doi.org/10.1172/JCI188314

الانترنت

https://doi.org/10.1172/JCI188314

مواد مشابهة